ArticleClinical and experimental pharmacology & physiology2026
Bosutinib Inhibits USP9X to Suppress the Proliferation, Migration, Angiogenesis and Glycolysis of Hepatocellular Carcinoma Cells by Deubiquitinating PLK1.
Article in Clinical and experimental pharmacology & physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular Carcinoma (HCC) is a matter of great global public health importance; however, its current therapeutic effectiveness is deemed inadequate, and the range of therapeutic targets is limited. This study aimed to explore the efficacy of Bosutinib (BOS) in HCC and the underlying molecular mechanism.
methodsBioinformatic analysis, machine learning, and online databases were used for screening targets and molecular docking studies. The mRNA level of mammalian polo-like kinase 1 (PLK1) was identified via real-time quantitative PCR. The protein expression of PLK1, PTK2, and USP9X was detected using western blot. Cell viability, apoptosis, and migration were evaluated by MTT, flow cytometry, and transwell assay. The angiogenesis capacity was determined using tube formation assay. The glucose consumption, lactate production, and ATP/ADP ratios were analysed using commercial kits. CO-IP assay was used to confirm the interaction between PLK1 and USP9X. A mouse model was used for exploring BOS in vivo. Immunochemistry was used to examine PLK1 and USP9X expression in tumours.
resultsThis study illustrated that BOS inhibited proliferation, migration, angiogenesis, and glycolysis of HCC cells. Bioinformatic analysis and machine learning identified PLK1 as a core gene related to the glycolysis of HCC. PLK1 was upregulated in HCC and correlated with an unfavourable prognosis. Further evaluation showed that the anti-tumour effects of BOS were impaired by PLK1 overexpression. In addition, BOS treatment inhibited PLK1 protein level, while its mRNA level was not affected. Moreover, Bosutinib inhibited USP9X to reduce the deubiquitination of PLK1. CO-IP assay indicated that reduced USP9X could enhance the ubiquitination of PLK1 and reduce protein stability. Finally, BOS showed anti-tumour effects in a mouse model.
conclusionThis study revealed that BOS inhibited cell proliferation, migration, angiogenesis, and glycolysis via suppressing USP9X, thus reducing deubiquitination of PLK1 in HCC, demonstrating the potential of BOS for the treatment of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.